ImageneBio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $13.12 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $10.75, a 36.59% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.87.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $13.12, a 786.49% increase from fiscal 2024.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.48, a 52.72% decline from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.13, a 59.40% decline from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.71, a 20.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.12 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $15.22 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | $1.48 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $1.48 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $1.43 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $3.13 10-K · filed 2024-03-12 | |||
| 2022-12-31 | $7.71 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $7.84 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $8.47 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $10.75 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $9.73 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $9.14 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $8.74 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $7.87 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |